

*Market Scope*<sup>®</sup>

# 2025 Exudative Retinal Disease Pharmaceuticals Market Report

Global Analysis for 2023 to 2029

**\$16.7B**

2025 MARKET  
FORECAST

**262**

COMPREHENSIVE  
PAGES

**29**

COMPETITOR  
PROFILES

**8**

GEOGRAPHIC AND  
ECONOMIC BREAKOUTS

# What's New

AUTHOR  
**Peter Downs**

PUBLISHED  
**October 2025**

The “2025 Exudative Retinal Disease Pharmaceuticals Market Report” includes a number of updates and fresh insights to provide a clearer picture of market dynamics, competitive positioning, and growth opportunities in this segment over the next five years.

New features include updated disease forecasts and revised sales projections for anti-VEGFs, broken down by active agent. The report also examines the impact of collapsing US prices for Lucentis and tracks anti-VEGF treatment shares by disease indication.

In addition, the report provides a thorough update on development-stage programs, offering the latest on investigational therapies and emerging mechanisms of action. Together, these enhancements provide a clearer picture of market dynamics, competitive positioning, and growth opportunities for the next five years.

## *Market Scope*

# 2025 Exudative Retinal Disease Pharmaceuticals Market Report

The “2025 Exudative Retinal Disease Pharmaceuticals Market Report” delivers a comprehensive analysis of anti-VEGFs and other therapies for exudative retinal diseases. It highlights key market trends, growth drivers, and future opportunities, with five-year forecasts in units and dollars for branded ocular anti-VEGFs, cancer drugs used off-label, biosimilars, and sustained-drug-delivery devices. The report also breaks down market share by product category and profiles 29 leading competitors, detailing their products, strategies, and market positioning. Key areas of coverage include:


- Disease landscape: Retinal diseases and their risk factors, plus diagnosis and treatment trends.
- Global perspective: Retina specialists and patterns of care across major markets.
- Current therapies: Pharmaceuticals and biologics already on the market for exudative retinal diseases.
- Pipeline insights: Investigational agents under development, across multiple mechanisms of action.
- Competitive landscape: Profiles of companies marketing therapies, plus additional firms with preclinical programs.

The report provides detailed market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, and biosimilars used for the treatment of exudative retinal diseases. The report also includes a separate forecast for sustained drug-delivery devices in retina and also delves into the development pipelines of eight categories of retinal pharmaceuticals: VEGF inhibitors, other vascular growth factor inhibitors, plasma kallikrein inhibitors, gene therapies, cell therapies, anti-inflammatories, Wnt signaling modulators, and other mechanisms of action.

**Revenue Market Share for Exudative Retinal Disease Pharmaceuticals by Product Type**



**Global Prevalence of Exudative Retinal Diseases by Region in 2025**



Market Scope designed this report to provide value to members of the ophthalmic industry who participate in the retinal pharmaceuticals market (or are weighing the option of doing so), market analysts, retina specialists, investors, and any other parties interested in the marketplace for these retinal treatments.

## How to Order

Order your “2025 Exudative Retinal Disease Pharmaceuticals Market Report” now at [www.market-scope.com](http://www.market-scope.com) or contact us directly via email or phone.



### ENTERPRISE LICENSE

2025 Exudative Retinal Disease  
Pharmaceuticals Market Report

**\$13,200**

*(Price includes a printable PDF and  
supplemental Excel file with all the  
tables and figures in the report)*



### SINGLE-USER LICENSE

2025 Exudative Retinal Disease  
Pharmaceuticals Market Report

**\$8,800**



Printed Copy

**\$250**



### ONE-YEAR SUBSCRIPTION

Ophthalmic Market  
Perspectives Newsletter

**\$1,650**



Monthly Paper Copies

**\$100**

314.835.0600 | [info@market-scope.com](mailto:info@market-scope.com)

## Our Process

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

